Clinicopathologic significance of GLUT1 expression and its correlation with Apaf-1 in colorectal adenocarcinomas

Table 2 Correlation between glucose transporter 1 expression and clinicopathologic factors in colorectal adenocarcinomas (n = 515) n (%)

Factors	n	Expression of GLUT1
		< 50% (%)	≥ 50% (%)	P value
		(n = 328)	(n = 187)
Age (yr)				0.0691
< 58	244	164 (67.2)	80 (32.8)
≥ 58	271	164 (60.5)	107 (39.5)
Gender				0.0091
Male	293	200 (68.3)	93 (31.7)
Female	222	128 (57.7)	94 (42.3)
Tumor location				0.5061
Colon	266	169 (63.5)	97 (36.5)
Rectum	249	159 (63.9)	90 (36.1)
Tumor size (cm)				0.5071
< 5.7	282	180 (63.8)	102 (36.2)
≥ 5.7	233	148 (63.5)	85 (36.5)
Tumor gross				0.2161
Fungating	239	157 (65.7)	82 (34.3)
Infiltrative	276	171 (62.0)	105 (38.0)
Tumor type				0.0451
Non-mucinous	489	307 (62.8)	182 (37.2)
Mucinous	26	21 (80.8)	5 (19.2)
Differentiation				0.0012
Well	21	19 (90.5)	2 (9.5)
Moderate	386	252 (65.3)	134 (34.7)
Poor	108	57 (52.8)	51 (47.2)
T category				0.2262
Tis, T1	16	13 (81.3)	3 (18.8)
T2	35	22 (62.9)	13 (37.1)
T3	452	286 (63.3)	166 (36.7)
T4	12	7 (58.3)	5 (41.7)
N category				< 0.0012
N0	226	170 (75.2)	56 (24.8)
N1	130	73 (56.2)	57 (43.8)
N2	159	85 (53.5)	74 (46.5)
M category				0.1451
M0	495	318 (64.2)	177 (35.8)
M1	20	10 (50.0)	10 (50.0)
AJCC stage				< 0.0012
0, I	41	30 (73.2)	11 (26.8)
IIA, IIB	183	139 (76.0)	44 (24.0)
IIIA, IIIB, IIIC	271	149 (55.0)	122 (45.0)
IV	20	10 (50.0)	10 (50.0)
Dukes stage				< 0.0012
A	12	10 (83.3)	2 (16.7)
B1, B2	208	156 (75.0)	52 (25.0)
C1, C2	275	152 (55.3)	123 (44.7)
D	20	10 (50.0)	10 (50.0)
Apaf-1				0.001
Negative	401	241 (60.1)	160 (39.9)
Positive	114	87 (76.3)	27 (23.7)

¹Fisher’s exact test,

²: χ² test for linear trend. GLUT1: Glucose transporter 1; Apaf-1: Apoptosis-activating factor-1.